Crossmark

In vitro evaluation of novel reverse transcriptase inhibitors TAF (tenofovir alafenamide) and OBP-601 (2,3-didehydro-3-deoxy-4-ethynylthymidine) against multi-drug resistant primary isolates of HIV-2

Crossref DOI link: https://doi.org/10.1016/j.antiviral.2018.10.018

Published Print: 2019-01

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Bártolo, Inês

Borrego, Pedro

Gomes, Perpétua https://orcid.org/0000-0003-3271-8255
Gonçalves, Fátima

Caixas, Umbelina

Pinto, Inês V.

Taveira, Nuno
Funding

Funding for this research was provided by:

FundaÃ§Ã£o para a CiÃªncia e a Tecnologia (VIH/SAU/0029/2011)

Instituto Nacional de CiÃªncia e Tecnologia para Excitotoxicidade e NeuroproteÃ§Ã£o

European and Developing Countries Clinical Trials Partnership

European Commission (SFRH/BPD/76225/2011)
License Information

Text and Data Mining valid from 2019-01-01

Text and Data Mining valid from 2019-01-01
More Information

This article is maintained by: Elsevier

Article Title: In vitro evaluation of novel reverse transcriptase inhibitors TAF (tenofovir alafenamide) and OBP-601 (2,3-didehydro-3-deoxy-4-ethynylthymidine) against multi-drug resistant primary isolates of HIV-2

Journal Title: Antiviral Research

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.antiviral.2018.10.018

Content Type: article

Copyright: © 2018 Elsevier B.V. All rights reserved.

Document is current

Any future updates will be listed below